Alvotech appoints Lisa Graver as CEO

Esme Needham | February 3, 2026 | Appointment | |  Alvotech, CEO 

Alvotech has announced the appointment of Lisa Graver as CEO, following the retirement of Róbert Wessman.

Wessman served as Chairman of Alvotech from its foundation in 2013 and as CEO from 2023. After stepping down as CEO in March 2026, he will continue to hold the role of Executive Chairman.

Graver brings significant expertise in leadership and operations. She has held roles across the global pharmaceutical industry, and has worked alongside Wessman for the last two decades. Prior to its acquisition by Lotus Pharmaceutical in 2025, Graver served as CEO of Alvogen, where she worked for over 15 years in roles including President and Executive Vice President.

Advertisement

She also previously held the role of Vice President, Intellectual Property at Actavis Switzerland and Innovest Enterprises, and Director, Intellectual Property at Alpharma.

Graver has been a member of Alvotech’s board since 2022. She will step down from the board upon taking up the role of CEO.

Wessman said: “Lisa has been a trusted partner to me for more than 20 years and brings deep leadership experience and understanding of this business. She has the full support of our board to build on our strong foundations and lead Alvotech forward.”

Related Content

Alvotech biosimilar receives EC marketing approval

The European Commission (EC) has granted marketing authorisation for Gobivaz, Alvotech’s first-in-market biosimilar of Simponi …

Alvotech and Advanz Pharma announce commercialisation agreement for Eylea biosimilar

Alvotech and Advanz Pharma have announced an exclusive partnership agreement surrounding the supply and commercialisation …

Alvotech and JAMP Pharma’s Jamteki gains marketing authorisation from Health Canada

Alvotech and JAMP Pharma have announced that Health Canada has granted JAMP Pharma marketing authorisation …

The Gateway to Local Adoption Series

Latest content